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Properdin enhances complement-mediated opsonization of targeted cells and particles
for immune clearance. Properdin occurs as dimers, trimers and tetramers in
human plasma, which recognize C3b-deposited surfaces, promote formation, and
prolong the lifetime of C3bBb-enzyme complexes that convert C3 into C3b, thereby
enhancing the complement-amplification loop. Here, we report crystal structures of
monomerized properdin, which was produced by co-expression of separate N- and
C-terminal constructs that yielded monomer-sized properdin complexes that stabilized
C3bBb. Consistent with previous low-resolution X-ray and EM data, the crystal
structures revealed ring-shaped arrangements that are formed by interactions between
thrombospondin type-I repeat (TSR) domains 4 and 6 of one protomer interacting with
the N-terminal domain (which adopts a short transforming-growth factor B binding
protein-like fold) and domain TSR1 of a second protomer, respectively. Next, a structure
of monomerized properdin in complex with the C-terminal domain of C3b showed
that properdin-domain TSR5 binds along the C-terminal α-helix of C3b, while two
loops, one from domain TSR5 and one from TSR6, extend and fold around the C3b
C-terminus like stirrups. This suggests a mechanistic model in which these TSR5 and
TSR6 “stirrups” bridge interactions between C3b and factor B or its fragment Bb, and
thereby enhance formation of C3bB pro-convertases and stabilize C3bBb convertases.
In addition, properdin TSR6 would sterically block binding of the protease factor I to
C3b, thus limiting C3b proteolytic degradation. The presence of a valine instead of a third
tryptophan in the canonical Trp-ladder of TSR domains in TSR4 allows a remarkable ca.
60◦-domain bending motion of TSR4. Together with variable positioning of TSR2 and,
putatively, TSR3, this explains the conformational flexibility required for properdin to form
dimers, trimers, and tetramers. In conclusion, the results indicate that binding avidity
of oligomeric properdin is needed to distinguish surface-deposited C3b molecules from
soluble C3b or C3 and suggest that properdin-mediated interactions bridging C3b-B
and C3b-Bb enhance affinity, thus promoting convertase formation and stabilization.
These mechanisms explain the enhancement of complement-mediated opsonization of
targeted cells and particle for immune clearance.
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INTRODUCTION
Complement plays an important role in humoral
immune responses against invading microbes, clearance of
apoptotic cells and debris, and modulation of adaptive immune
responses (1, 2). Initiation of the complement cascades through
either the classical, lectin or alternative pathway converges in
the formation of C3 convertase complexes, consisting of C3b
and protease fragment Bb forming C3bBb, which generates a
positive-feedback loop that amplifies the complement cascade
yielding massive deposition of C3b onto the targeted surface. At
this critical step, the complement system is heavily regulated.
Intrinsically, the non-covalent C3bBb enzyme dissociates
irreversibly into its components C3b and Bb with a half-life time
of 1–2min (3, 4). Host regulators, such as factor H (FH), decay-
accelerating factor (DAF), and membrane-cofactor protein
(MCP), provide protection of host cells against complement
attack (5). FH and DAF inactivate the C3 convertase by
promoting dissociation of C3bBb into C3b and Bb (5). FH and
MCP have cofactor activity that enables factor I (FI) to bind and
cleave C3b into iC3b, rendering it inactive, and unable to form
new convertases (5, 6).
Properdin is the only known intrinsic positive regulator
of the complement system (7–9). Properdin stabilizes C3bBb,
increasing the half-life of the enzyme complex 5- to 10-
fold (10). In addition, it has been indicated that properdin
accelerates formation of pro-convertases C3bB (11) and reduces
C3b inactivation by FI (12, 13). Furthermore, it has been
suggested that, for some bacterial surfaces, apoptotic/necrotic
cells or renal epithelial cells, properdin can function as a
pattern recognition molecule, forming an initiating platform
for the alternative pathway (14–19), although others claim that
properdin binding to surfaces depends on initial C3b deposition
(20, 21). Properdin deficiency results in increased susceptibility
to infection by Neisseria meningitidis (22), with high mortality
rates compared to deficiency of protein components (C5–C9)
of the terminal pathway (23). In addition, properdin deficiency
has been associated with other diseases, such as otitis media and
pneumonia, as reviewed in Chen et al. (23).
Human properdin is an oligomeric plasma protein that is
present in serum at relatively low concentrations (4–25µg/ml)
(8), compared to other complement components [∼1.2 mg/ml
for C3 and ∼0.6 mg/ml for factor B (FB)] (24). In contrast
to most other complement proteins, properdin is not produced
by the liver, but expressed locally by various immune cells
including neutrophils, monocytes, and dendritic cells (23, 25, 26).
Therefore, at sites of inflammation properdin concentrations
might be considerably higher than serum concentration. In
Abbreviations: ADP, atomic displacement parameters; Bb, cleavage product b of
factor B; C3, complement component 3; C3b, cleavage product b of complement
component 3; CTC, C-terminal C345c; DAF, decay-accelerating factor; EM,
negative-stain electron microscopy; FB, factor B; FH, factor H; FI, factor I; IMAC,
immobilizedmetal affinity chromatography;MCP,membrane-cofactor protein; Pc,
cleaved properdin; PDB, protein data bank; rmsd, root-mean square deviation;
SCIN, Staphylococcus aureus inhibitor; SEC, size exclusion chromatography; SPR,
surface-plasmon resonance; STB, short transforming-growth factor B binding
protein-like; TSR, thrombospondin type-I repeat.
serum, properdin is predominantly found as dimers, trimers and
tetramers in the percentage ratios of 26:54:20% (8), although
a small amount of pentamers and hexamers are also found
(13, 27). At physiological conditions, no exchange between the
oligomeric states of properdin is observed (8), but higher order
aggregates form upon freeze-thaw cycles (28). A properdin
protomer consists of 442 amino-acid residues with a fully-
glycosylated molecular weight of 53 kDa (29). Properdin forms
seven domains, anN-terminal domain of unknown fold, followed
by six thrombospondin type I repeats (TSR) domains (29). TSR
domains consist of∼60 amino-acid residues and have a thin and
elongated shape (30), formed by only three anti-parallel peptide
chains. The TSR-fold is structurally stabilized by regions forming
β-sheets, three conserved disulphide bonds and by a structural
WRWRWRmotif [also referred to as Trp-ladder (31)] that forms
a stack of alternating tryptophans and arginines throughpi-cation
interactions (30). The N-terminal domain has often been referred
to as TSR0 (9, 13, 32, 33), despite missing the WRWRWR motif.
Properdin is highly post-translationally modified, resulting in
14–17 C-mannosylated tryptophans, four O-linked glycans, and
one N-linked glycan (34, 35). Negative-stain electron microscopy
(EM) has shown that oligomeric properdin forms ring-shaped
vertices connected by extended and flexible edges (13, 27). Based
on EM images and TSR domain deletions, it has been proposed
that the vertices consist of interlocking C- and N-terminal
domains of properdin protomers and the edges consist of three
bridging TSR domains from a single protomer (13, 27, 29).
EM images indicate that each properdin vertex binds a single
C3bBb complex (13). Higgens et al. (29) showed that domain
deletions of properdin TSR domains 4 through 6 results in altered
oligomerization and loss of function, whereas deletion of TSR3
has no significant effect on either oligomerization or properdin
function. Pedersen et al. (32) introduced a proteolytic cleavage
site between properdin-domains TSR3 and TSR4 and thereby
generated single properdin vertices for crystallographic studies.
A 6.0-Å resolution crystal structure of a single properdin vertex
in complex with C3bBb (32) [that was stabilized by S. aureus
inhibitor SCIN (36)] showed that properdin binds to the α-
chain region of C3b, revealing density adjacent to the C-terminal
C345c (CTC) domain of C3b. However, the resolution of the
crystallographic data (PDB ID: 5M6W) did not allow atomic
modeling of the cleaved properdin (Pc) fragment.
In this study, we present the production of monomerized
properdin variants that stabilize C3bBb using co-expression
of properdin N- and C-terminal fragments. We determined
crystal structures of monomerized properdin and its complex
with the CTC domain of C3/C3b with diffraction data up to
2.0- and 2.3-Å resolution, respectively. These structures reveal
the fold of the properdin N-terminal domain, the properdin
domain arrangement that yields the properdin ring-shaped
vertex structure, stabilization of Trp-Arg interactions in the
Trp-ladder provided by tryptophan C-mannosylation, structural
flexibility of the TSR4 domain and functionally important
extensions of the TSR5 and TSR6 domains. The structure of
monomerized properdin in complex with the C3/C3b-CTC
domain identifies the specific regions of properdin involved in
binding FB and Bb that enhance pro-convertase formation and
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convertase stabilization, respectively. Finally, we propose amodel
for properdin oligomers stabilizing convertases on surfaces based
on re-analysis of the 5M6W-diffraction data set.
MATERIALS AND METHODS
Molecular Cloning and Construct Design
Human properdin (UniProtKB-P27918) cDNA was obtained
from Open Biosystems (Dharmacon Inc.). Domain boundaries
were chosen based on both UniProt assignment and crystal
structures of thrombospondin I domains TSR2 and TSR3 (PDB
ID: 1LSL) (30). In addition to full-length properdin (res. 28–
469), four N-terminal constructs were created, PN1 (res. 28–
132), PN1
′
(res. 28–134), PN12 (res. 28–191), and PN123 (res.
28–255), comprising the first two, three, and four N-terminal
domains of properdin; and P456 (res. 256–469) comprising the
three C-terminal domains. The N-terminal domain boundary
of the C3/C3b-CTC domain (res. 1517–1663) was chosen based
on the structure of C3b [PDB ID: 5FO7 (37)]. All inserts were
generated by PCR using clone specific primers that include a
5′ BamHI restriction site that results in an N-terminal Gly-Ser
cloning scar in all constructs and a NotI restriction site at the 3′
end of the insert. The NotI site results in a C-terminal extension
of three alanine’s in all constructs, except for PN12 and C3/C3b-
CTC, where a stop codon was introduced prior to the NotI
site. All inserts were cloned into pUPE expression vectors (U-
Protein Express BV, Utrecht, the Netherlands). For small-scale
(4ml) expression tests, one of the constructs (either the N- or
C-terminal fragment) included a 6x-His purification tag. In large-
scale co-expressions P456 included a C-terminal 6xHis-tag, with
no tag on the N-terminal constructs. Similarly, constructs for
full-length properdin included a C-terminal 6xHis-tag and the
C3/C3b-CTC construct contained an N-terminal 6xHis-tag.
Recombinant proteins were transiently expressed in Epstein-
Barr virus nuclear antigen I (EBNA1)- expressing, HEK293
cells (HEK293-EBNA) (U-Protein Express BV, Utrecht, the
Netherlands). For crystallization purposes, proteins were
expressed in GnTI− HEK293-EBNA cells. N-terminal and
C-terminal properdin fragments were co-expressed using a 1:1
DNA ratio. Cells were grown in suspension culture at 37◦C
for 6 days post-transfection. For each culture, supernatant was
collected by a low-speed spin (1,000 × g for 10min), followed
by a high-speed spin (4,000 × g for 10min) to remove any
remaining cell debris. Subsequently, 3 ml/L Ni-Sepharose
Excel beads (GE Healthcare) was added to the supernatant
and the mixture was incubated for 2 to 16 h with constant
agitation at 4◦C. The beads were washed with 10-column
volumes of buffer A (20mM HEPES pH 7.8, 500mM NaCl)
and 10 column volumes of buffer A supplemented with 10mM
imidazole. Bound protein was subsequently eluted with buffer
A supplemented with 250mM imidazole. For small-scale (4ml)
expression tests of properdin fragments no further purification
steps were performed, whilst for large-scale (1 L) expressions,
pooled fractions were concentrated, and further purified by size-
exclusion chromatography (SEC). PN12/456 for SPR was purified
with a Superdex 200 16/600 (GE Healthcare) using 25mM
HEPES pH 7.8, 150mM NaCl as the running buffer. All other
properdin complexes were purified on a Superdex 200 10/300
Increase (GE Healthcare) column using either 20mM HEPES
pH 7.4, 150mM NaCl (properdin, PN1/456, PN1
′/456) or 25mM
HEPES pH 7.8 with 100mM NaCl (PN12/456 for crystallizations)
as the running buffer. The C3/C3b-CTC domain was purified on
a Superdex 200 16/600 (GE Healthcare) in 20mM HEPES pH
7.4, 150mM NaCl. Human wild type FB, catalytically inactive
(S699A) double-gain-of-function (D279G, N285D) FB mutant
(FBdgf‡) (38), factor D (FD), DAF1-4 and Salp20 were purified
as described previously (39–41). C3 and C3b were purified
from human plasma as described in Wu et al. (40). Full-length
properdin was stored at 4◦C and all other proteins were flash
frozen by plunging into liquid N2 and stored at−80◦C.
C3 Convertase Stability Assay
To generate C3 convertase, purified C3b (obtained after cleavage
of human serum-derived C3) was mixed with catalytically
inactive FBdgf‡ at a ratio of 1:1.1 in the presence of 5mMMgCl2.
After incubation for 5min at 37◦C, FD was added to a ratio of
C3bB:FD of 1:0.1 and the mixture was incubated for another
5min at 37◦C, after which the C3 convertase was stored on ice
till further use. C3 convertase was diluted to 1.5µM with ice-
cold buffer (20mM HEPES pH 7.4, 150mM NaCl and 5mM
MgCl2). Either 6µM PN1/456 or PN12/456 or an equal volume of
buffer (control) was added to the C3 convertase in a ratio of 1:2
resulting in a final concentration of 2µMPN1/456 or PN12/456 and
1µM C3 convertase. The mixture was incubated at 37◦C for 1 h
and subsequently put on ice. The amount of C3 convertase was
analyzed by analytical SEC using a Superdex 200 10/300 Increase
pre-equilibrated with 20mM HEPES pH 7.4, 150mM NaCl, and
5mMMgCl2 at 18◦C on a Shimadzu FPLC.
Surface-Plasmon Resonance
C3b was generated from C3 through the addition of FB and
FD to a C3:FB:FD molar ratio of 1:0.5:0.03 in the presence
of 5mM MgCl2 and incubation at 37◦C. At 10min intervals
fresh FB was added to ensure complete conversion of C3 to
C3b. Subsequently, C3b was biotinylated on the free cysteine
that is generated after hydrolysis of the reactive thioester (42);
EZ-Link Maleimide-PEG2-Biotin (Thermofisher) was added to
a final concentration of 1mM to the freshly produced C3b
(13µM) and the mixture was incubated for 3 h at room
temperature. C3b was separated from unreacted Biotin-Peg2-
Maleimide by SEC using a S200 10/300 increase column pre-
equilibrated in 20mM HEPES pH 7.4, 150mM NaCl. Purity
and conversion of C3 to C3b were analyzed by SDS-PAGE.
To analyze equilibrium binding to monomerized properdin, we
used PN1
′/456 that includes an additional Cys-Pro (res. 133–134)
at the C-terminus of TSR1. PN1
′/456 (45µM) was biotinylated
as described for C3b and separated from excess biotin with a
5mLHiTrap Desalting column (GEHealthcare) pre-equilibrated
in 20mM HEPES pH 7.4, 150mM NaCl. Biotinylated proteins
were spotted on a SensEye P-Strep chip (SensEye) at 50 nM for
60min with a continuous flow microspotter (CFM, Wasatch).
Equilibrium binding kinetics were analyzed using an IBIS-MX96
(IBIS Technologies). All experiments were performed in 20mM
HEPES pH 7.4, 0.005% (v/v) Tween-20, 150mM NaCl at 4
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µl/s. For experiments involving C3bB and C3bBb the buffer was
supplemented with 5mM MgCl2. Analyses at low ionic strength
were performed at a NaCl concentration of 50mM.Analytes were
injected from low to high concentration in 14 2-fold incremental
steps. In equilibrium binding analyses involving C3bB or C3bBb,
C3bB was generated on a C3b coated SPR surface by injecting
100 nM FBdgf‡ for 5min prior to each analyte injection. C3bBb
was generated from C3bB by injections of 100 nM FD for
5min after each FB injection. Where indicated, DAF1-4 (1µM),
FD (100 nM), and/or Salp20 [1µM for experiments with C3b
alone and 5µM in experiments with C3 (pro) convertase] were
injected, to regenerate the C3b surface. Salp20, a properdin
inhibitor from deer tick (43), was required to dissociate full
length properdin from C3b. In all experiments, the SPR surface
was washed with buffer supplemented with 1M NaCl at 8
µl/s for 30 s at the end of each cycle. Temperature was kept
constant at 25◦C. Prism (GraphPad) was used for data analysis.
KD′s were determined by fitting the end point data to Y =
Bmax∗ XKD+X + Background.
Crystallization, Data Collection, and
Structure Determination
PN1/456 and the C3/C3b-CTC domain were dialyzed overnight
at 4◦C using a 3.5 kDa cutoff Slide-A-Lyzer Mini Dialysis
Unit (Thermo Scientific) against 10mM HEPES, 50mM NaCl,
pH 7.4. The N-linked glycan on Asn428 of PN1/456 was
removed by including 1% v/v EndoHF (New England BioLabs)
during the dialysis. PN1/456, PN12/456, and the C3/C3b-CTC
domain were concentrated to 8.7 mg/ml, 10 mg/ml, and 10.3
mg/ml, respectively.
Crystals were obtained using the sitting drop vapor diffusion
method at 18◦C. Crystals of PN12/456 were grown in 100mM
sodium citrate pH 5.5 and 20% (w/v) PEG 3,000 and
cryoprotected by soaking in mother liquor supplemented with
25% (v/v) glycerol. Crystals of PN1/456 were grown in 0.2M
potassium sulfate and 20% (w/v) PEG 3350, and cryoprotected by
soaking in mother liquor supplemented with 25% (v/v) ethylene
glycol. PN1/456 and C3/C3b-CTC were mixed in a 1:1 molar ratio
at 8 mg/ml and crystals were grown in 8% v/v Tacsimate pH
5.0 and 20% (w/v) PEG 3350, and cryoprotected by soaking in
mother liquor supplemented with 25% glycerol. After harvesting,
crystals were cryo-cooled by plunge freezing in liquid N2. All
diffraction data were collected at the European Synchrotron
Radiation Facility (ESRF) on beamlines ID29 (PN12/456) and
ID23-1 (PN1/456-CTC, PN1/456). The diffraction images were
processed with DIALS (44) and the integrated reflection data
were then anisotropically truncated with the STARANISO web
server (45).
Structures were solved bymolecular replacement using Phaser
(46). Atomic models were optimized by alternating between
refinement using REFMAC (47), and manual building in Coot
(48). C- and O-linked glycosylation restraints were generated
within Coot, using ACEDRG (49). The structure of PN12/456 was
refined with restraints generated from PN1/456 using ProSMART
(50). Data was deposited at the RSCB Protein Data Bank (51)
with PDB IDs 6S08, 6S0A, and 6S0B. We also re-analyzed
data deposited for Pc in complex with C3bBb-SCIN (32) (PDB
ID: 5M6W). An initial position for the properdin molecule
was obtained by superposing our PN1/456-CTC model onto
the CTC domain of the two C3b molecules in the model
deposited by Pedersen et al. (32). Subsequently, TSR2 from
PN12/456 was added and manually adjusted to fit the density.
In addition, for one of the two copies in the asymmetric unit,
density corresponding to TSR3 was apparent. A TSR model
derived from TSR2 from thrombospondin-1 [PDB ID: 1LSL
(30)], containing the canonical cysteines and Trp-ladder residues,
but otherwise consisting of poly-alanines, was placed into this
density. The resulting model was further refined using the
LORESTR refinement pipeline (52). Coordinates of the re-refined
properdin-C3bBb-SCIN complex (PDB ID: 5M6W) are available
from the authors upon request.
RESULTS
Production of Monomerized Properdin by
Co-expression of N- and C-Terminal
Fragments
We generated N-terminal constructs of properdin, comprising
the N-terminal domain of unknown fold and TSR1, TSR2, and
TSR3, denoted PN1 (res. 28–132), PN12 (res. 28–191), and PN123
(res. 28–255), and a C-terminal construct comprising TSR4,
TSR5, and TSR6, P456 (res. 256–469). Small scale expression
of isolated His6-tagged terminal fragments followed by IMAC-
affinity purification resulted in no significant expression of
P456, whereas co-expression of N- and C-terminal fragments
yielded both fragments in ∼1:1 ratio in all cases. We
therefore decided to continue with large-scale co-expression
of the two shorter N-terminal fragments, PN1 and PN12,
with P456 with the latter carrying a C-terminal His6-tag (see
section Materials and Methods). IMAC-affinity purification
yielded stable protein complexes consistent with one-to-
one non-covalent complexes of PN1 with P456 and PN12
with P456, denoted PN1/456 and PN12/456, respectively. Both
PN1/456 and PN12/456 yielded monodisperse peaks during size-
exclusion chromatography (SEC) consistent with a single
monomerized species (Figures 1A,B), whereas recombinant full-
length properdin produced a SEC spectrum with multiple peaks
consistent with a mixture of dimeric, trimeric, and tetrameric
properdin (Figure 1C). Large-scale expression and purification
of PN1/456 and PN12/456 yielded ca. 5-8mg per liter culture.
Monomerized Properdin Binds and
Stabilizes C3 Convertases
Stabilization of C3 convertases was analyzed by monitoring the
decay of pre-formed C3bBb in the presence and absence of
properdin (Figures 1D,E). In the absence of properdin,∼75% of
the C3bBbdgf‡ was dissociated into C3b and Bbdgf‡ after 1 h at
37◦C, whereas in the presence of PN1/456 or PN12/456 dissociation
of C3bBbdgf‡ was reduced to ∼20–25%, indicating that PN1/456
and PN12/456 stabilized C3 convertase to a similar extent.
Binding affinities of PN12/456 for C3b, pro-convertase C3bB
and convertase C3bBb were determined using surface plasmon
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FIGURE 1 | Purification of properdin and stabilization of C3 convertase.
(A) SEC elution profile and SDS-page of PN1/456. (B) SEC elution profile and
SDS-page of PN12/456. (C) SEC elution profile and SDS-page of properdin,
pooled fractions are indicated by the red line. (D) SEC elution profiles of C3
convertase (C3bBbdgf‡) incubated in the presence (red dashed line) or
absence (green line) of PN1/456 for 1 h at 37◦C compared to the sample at t =
0 (black line). (E) As panel (D) but with PN12/456 instead of PN1/456.
resonance (SPR) equilibrium binding experiments. C3b was
biotinylated at its reactive thioester, which allows coupling
to streptavidin-coated SPR sensor chips in an orientation
reflecting that of surface bound C3b. Under physiological salt
conditions, PN12/456 bound C3b with a KD of 6.8 ± 0.2µM,
which is similar to the KD of 7.8µM reported by Pedersen
et al. for single properdin vertices generated by proteolytic
cleavage (32), but much lower than the apparent KD of 22
± 2 nM for oligomeric properdin (Figure 2). At low ionic
strength (50mM NaCl), interaction between PN12/456 and C3b
appeared much stronger with a KD of 0.69 ± 0.04µM. Next,
we generated pro-convertases C3bB and convertases C3bBb on
the chip (see section Materials and Methods). PN12/456 bound
C3bB and C3bBb with a KD of 98 ± 2 nM and 34 ± 1 nM,
respectively, (Figure 3), whereas properdin oligomers bound
with an apparent KD of 4.6± 1 nM and 4.4± 1 nM, respectively.
Thus, PN12/456 binds to C3b, C3bB and C3bBb (in order of
increasing affinity).
Previous data (13, 32) suggested that the main interaction
site of properdin with C3b is localized on the C3b-CTC
domain. Therefore, we analyzed binding of the isolated C3/C3b-
CTC domain to a PN1
′/456 coated SPR chip. The C3/C3b-
CTC domain binds PN1
′/456 with a KD of 18.6 ± 1.6µM,
which is comparable to the KD of 6.8 ± 0.2µM we observed
for C3b and PN12/456, suggesting that the primary binding
interface of C3b is indeed provided by the CTC domain
(Figure 2). Overall, these data indicated that the non-covalent
complexes PN1/456 and PN12/456 bound C3b and stabilized
C3bBb similar to an excised monomeric version of full-length
oligomeric properdin.
Structure Determination of Monomerized
Properdin and Its Complex With
C3/C3b-CTC
PN1/456 and PN12/456 crystallized as thin plates, and resulted
in highly anisotropic data, with anisotropic resolution limits
of 2.0–2.9 Å and 2.5–3.9 Å, respectively. PN1/456 in complex
with C3/C3b-CTC crystallized as long rods and pyramids.
While the pyramid-shaped crystals showed poor diffraction,
PN1/456-CTC rod-shaped crystals diffracted anisotropically with
resolution limits of 2.3–2.7 Å. Data collection statistics are shown
in Table 1.
We first determined the crystal structure of PN1/456 in
complex with C3/C3b-CTC using the C3b-CTC domain [PDB
ID: 5FO7 (37)] as a search model for molecular replacement with
Phaser (46). A minimal TSR model was generated with Sculptor
(53) using a sequence alignment (54) of TSR1, TSR4, TSR5, and
TSR6 in combination with TSR2 from thrombospondin-1 [PDB
ID: 1LSL (30)]. This model was then used in subsequent rounds
of molecular replacement, which resulted in the positioning
of TSR1, 4, 5, and half of TSR6 accounting for ∼80% of the
total structure. The N-terminal domain and the remaining part
of TSR6 were built using Coot (48). Structure determination
continued with further rounds of model building (48) and
structure refinement (47), until convergence. The refined model
of PN1/456 taken from PN1/456-CTC was used in molecular
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FIGURE 2 | Surface Plasmon Resonance (SPR) analysis showing interaction of properdin with C3b and the C3b/C3 CTC domain. SPR sensorgrams (left) and
equilibrium binding plots (right). (A) Interaction of PN12/456 (concentration range: 4.9 × 10−3 µM to 40µM) with a C3b coated chip at physiological ionic strength
(150mM NaCl). (B) interaction of PN12/456 (concentration range: 1.2 × 10−3 µM to 10µM) with a C3b coated chip at low ionic strength (50mM NaCl). (C)
Interaction of properdin (concentration range: 1.2 × 10−4 µM to 1µM) with a C3b coated chip. (D) Binding of the C3/C3b CTC domain (concentration range: 2.4 ×
10−2 µM to 200µM) to a PN1
′/456 coated chip. The data point at 200µM C3/C3b CTC was considered as an outlier and was not used to determine the KD. Where
indicated Salp20 was used to regenerate the surface.
replacement to solve the structures of PN1/456 and PN12/456.
After initial placement, PN12/456 was completed by molecular
replacement using the TSR model. Model refinement statistics
for all structures are listed in Table 1 final models are shown
in Figure 4.
Fold of the Properdin N-Terminal Domain
The crystal structure of properdin revealed that the N-terminal
domain (res. 28–76) adopts a compact globular fold, containing
two β-sheets and a single α-helix stabilized by three disulphide
bonds (Figure 4B). A homology search using the Dali server
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FIGURE 3 | SPR analysis showing interaction of properdin with C3 pro-convertase. SPR sensorgrams (left) and equilibrium binding plots (right). C3bBdgf‡ and
C3bBbdgf‡ were generated on the chip by injecting FBdgf‡ or FBdgf‡ and subsequently FD on a C3b coated chip. (A) Interaction of PN12/456 (concentration range:
2.4 × 10−4 µM to 2µM) with C3bBdgf‡. (B) Interaction of PN12/456 (concentration range: 1.2 × 10−4 µM to 1µM) with C3bBbdgf‡. (C) Interaction of properdin
(concentration range: 6.1 × 10−5 µM to 0.5µM) with C3bBdgf‡. (D) Interaction of properdin (concentration range: 6.1 × 10−5 µM to 0.5µM) with C3bBbdgf‡.
Where indicated Salp20, FD, and DAF were used to regenerate the surface.
(55) indicated that the properdin N-terminal domain is most
closely related to transforming growth factor β binding protein-
like (TB) domains; the closest structural homologs for the
properdin N-terminal domain are the TB domains of human
follistatin (PDB ID 5JHW, chain C/D, Dali z-score 5.9), and
follistatin-like 3 (PDB ID 3B4V chain H, Dali z-score 5.6) and
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TABLE 1 | Diffraction-data collection and refinement statistics.
PN1/456-CTC PN1/456 PN12/456
Wavelength (Å) 0.9789 0.9789 0.9763
Resolution range 63.08–2.31 (2.60–2.31) 79.61–2.03 (2.31–2.03) 102.88–2.52 (2.71–2.52)
Space group P 21 21 21 C 1 2 1 I 4 2 2
Cell dimensions
a, b, c (Å) 71.47, 71.50, 134.18 112.00, 114.86, 39.82 114.75, 114.75, 232.26
α, β, γ (◦) 90, 90, 90 90, 99.56, 90 90, 90, 90
Total reflections 113,523 (7,011) 60,691 (2,967) 142,792 (8,720)
Unique reflections 21,145 (1,538) 17,424 (871) 16,212 (810)
Multiplicity 5.4 (4.6) 3.5 (3.4) 8.8 (10.8)
Completeness (Spherical) 68.6 (17.1) 54.5 (8.7) 60.5 (15.5)
Completeness (ellipsoidal) 90.3 (71.1) 89.5 (61.1) 93.6 (71.3)
Diffraction limits and
eigenvectors of ellipsoid
fitted to diffraction cut-off
surface: (Å)
a*: 2.705
b*: 2.647
c*: 2.287
0.952 a*-0.307 c*: 2.027
b*: 2.289
0.926 a* + 0.377 c*: 2.979
a*: 2.515
b*: 2.515
c*: 3.914
Mean I/sigma(I) 11.1 (1.5) 3.4 (1.5) 7.5 (1.5)
Wilson B-factor (Å2) 47.02 23.66 53.29
R-merge 0.100 (1.267) 0.161 (1.249) 0.185 (1.639)
R-pim 0.047 (0.637) 0.100 (0.784) 0.089 (0.726)
CC1/2 0.996 (0.560) 0.982 (0.469) 0.996 (0.629)
Reflections used in
refinement
21,137 17,421 16,209
R-work/R-free 0.230/0.277 0.212/0.248 0.248/0.267
Number of non-hydrogen
atoms
3,645 2,589 2,906
Macromolecules 3,452 2,343 2,705
Ligands 123 130 190
Solvent 70 116 11
RMS (bonds) (Å)/(angles) (◦) 0.014/1.82 0.014/1.87 0.014/1.97
Ramachandran outliers (%) 0.67 0 0.55
Rotamer outliers (%) 3.65 2.38 7.42
Clashscore 2.80 5.92 8.24
Average ADP (Å2) 52.83 29.76 64.02
Macromolecules 52.88 29.62 63.25
Ligands 58.33 34.92 76.76
Solvent 40.23 26.87 32.57
Values in parentheses are for reflections in the highest resolution shell. The * denotes reciprocal space.
the hyb2 and TB4 domains of human Fibrillin-1 (respectively:
PDB ID 2W86, Dali z-score 5.4; PDB ID: 1UZQ, Dali z-
score 5.2) (56). TB domains are characterized by 8 cysteines
resulting in a 1–3, 2–6, 4–7 and, though not always present,
5–8 disulphide pattern, where the 5–8 disulphide links the
domain core to the C-terminal tail and Cys3, 4, and 5 form a
characteristic triple cysteine motif (57, 58). The properdin N-
terminal domain contains three disulphides that match the 1–3,
2–6, 4–7 disulphides of the TB core andmisses the 5–8 disulphide
and connecting C-terminal tail. We refer to this as the short TB
(STB) fold.
Properdin-TSR Domains
Five of the six TSR domains of properdin are present in the
structures of PN1/456, PN12/456, and PN1/456-CTC (Figure 4). The
TSR domains of properdin display minor to major variations
from the TSR domain fold as described for the structures of
TSR2 and 3 from thrombospondin-1 (30); these are shown
schematically in Figure 4B.
Compared to TSR2 and 3 from thrombospondin-1, properdin
domain TSR1 (res. 77–133) lacks a five-residue β-bulge
preceding β-strand C, referred to as “jar-handle” motif, that
provides H-bonding interactions with the indole ring of the
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FIGURE 4 | Overview of properdin structures. (A) From left to right: PN1/456, PN12/456, and PN1/456-CTC. Structures are depicted in cartoon representation with a
semi-transparent molecular surface (top row) and as ADP cartoon putty (bottom row). ADP colors for all three structures are on the same scale of 10–140 Å2.
(B) Cartoon representation of individual properdin domains; the TSR Trp-ladder residues, disulphides, and glycans are depicted as sticks. A schematic representation
of the general TSR domain topology is included, showing the three strands and the position of the WxxWxxW and RxRxR motifs; the three disulphides are
represented by dashed lines. TSR domains are shown with the Trp-ladder in approximately the same orientation. TSR1 and TSR2 were taken from FPN12/456, TSR6
from FPN1/456-CTC and STB, TSR4 & TSR5 from FPN1/456. Unless stated otherwise, domains are colored as follows: STB (purple), TSR1 (blue), TSR2 (coral), TSR4
(yellow), TSR5 (green), TSR6 (red) from properdin, and the C3/C3b CTC domain (gray).
Frontiers in Immunology | www.frontiersin.org 9 September 2019 | Volume 10 | Article 2097
van den Bos et al. Structures of Properdin and Properdin/C3b-CTC
FIGURE 5 | Disulphides at the properdin TSR1-TSR2 interface. (A) Cartoon
representation of the TSR1-TSR2 interface in PN12/456 with disulphides
represented as sticks. The terminal Cys133 of TSR1 forms the canonical
disulphide with C93 in theTSR1 A-B loop, whereas Cys132 forms a disulphide
with Cys170 in the B-C loop of TSR2. (B) The TSR1 distal end in PN1/456
showing the “incorrect” disulphide between Cys132 and Cys93. Electron
density is shown at 1-rmsd contour level. Colors are as follows: TSR1 (blue),
TSR2 (coral), TSR6 (red), and disulphides are shown in yellow.
first tryptophan of the Trp-ladder. Instead of this β-bulge,
the C-strand in TSR1 is extended by two residues and the
typical H-bonding interactions of the β-bulge are substituted
by Ser112 in the B-C loop, which is observed within H-
bond distance of the Trp80 indole ring. In the TSR1-Trp
ladder, a glutamine residue resides at the position of the
third arginine, resulting in a lost pi-cation interaction with the
last Trp. Preceding the prototypical C-terminal Cys (Cys133),
TSR1 contains an additional cysteine (Cys132) that connects
to Cys170 of TSR2, as observed in the structure of PN12/456
(Figure 5A). However, our construct PN1 is terminated at
Cys132. As a consequence, we observed a non-native disulphide
bond between Cys93-Cys132 and increased disorder at the C-
terminal end of TSR1 in the structure of PN1/456 and PN1/456-
CTC (Figure 5B); however, the overall fold of TSR1 was
not affected.
TSR2 (res. 134–191) displayed the consensus TSR fold,
with only minor deviations besides the additional cysteine
(Cys170).However, this domain was not well-defined by the
density as reflected by its high atomic displacement parameters
(ADP) (Figure 4A).
TSR4 (res. 256–312) showed striking variations in the
structures of PN1/456, PN12/456, and PN1/456-CTC (Figures 6A,B).
In the Trp-ladder of TSR4 the canonical third tryptophan is
replaced by a valine (Val266). A comparison of TSR4 from all
three structures shows that TSR4 displays a bending-like motion
at this position (Figures 6A,B). The distal part of TSR4 is held in
place by interaction with the STB domain, but the proximal part,
where the short Trp-ladder, comprising Trp260 and Trp263 in
strand A, Arg282 in strand B and Arg302 in strand C, is located
is at a different position in each of the three structures resulting
in a distance of 28.3 Å between the Cα atoms of TSR4 Ser255 in
PN1/456 and PN12/456.
TSR5 (res. 313–376) displayed well-defined electron density
in all three structures and closely resembled the TSR-consensus
fold. However, the canonical third arginine in strand B of
TSR5 is replaced by Gln344. Gln344 forms a H-bond with
Arg368 from strand C and Arg364 is in pi-cation stacking
conformation with Trp324. Thus, the stacking of Trp-ladder
residues is effectively conserved. The most striking feature of
TSR5 is a six-residue insertion (res. 328–333) (29), in the A-B
loop betweenCys327 andCys337 that forms a loop that protrudes
from the TSR domain.
TSR6 (res. 377–469) showed a larger deviation from the
typical TSR-fold and has a boomerang-like appearance, due to
a 22 residue-long insertion (res. 412–434) (29) in the B-C loop.
This insertion forms a β-hairpin loop that protrudes from the
TSR6-core (Figure 4B). The core part of TSR6 makes an angle of
147◦ with TSR5, pointing toward TSR1, and the TSR6 β-hairpin
protrudes at a 70◦ angle from the domain core toward and
beyond TSR5. Residues 430–438 from the TSR6 β-hairpin are
part of a β-sheet with the end of strandC fromTSR5 (Figure 7). A
hydrophobic core consisting of Pro435, Tyr371, and Ile373 from
TSR5 and Leu378, Leu411, Pro412, Tyr414, Val418, Val429, and
Phe431 from TSR6 stabilizes the base of the β-hairpin. Similar to
TSR1, TSR6 lacks a “jar-handle” motif. In this case, the jar-handle
H-bonding interactions are substituted by the backbone carbonyl
from Glu440 in the B-C loop, which forms a H-bond with NH1
of the first Trp, Trp382, of the Trp-ladder. In TSR6 Arg405 is
not stabilized by a residue from strand C and both Arg405 and
Trp382 are not in a pi-cation stacking conformation and thus do
not contribute to the stability of the Trp-ladder.
Properdin Glycosylation
The tryptophans of TSR Trp-ladders are typically C-type
mannosylated, where the C1 of an α-mannose is attached
to the C2 in the indole ring of the Trp (34, 35, 59).
We could clearly identify C-mannosylation for 11 out of
14 Trp-ladder tryptophans (Figure 4B). For the majority of
these, we observe that the O2 oxygen of the mannosyl-Trp
moiety interacts with its backbone nitrogen, whereas the O5
and O6 oxygens form H-bonds with the side chain of the
adjacent Arg, which further stabilizes the TSR domain fold
(Figures 6B,C). In addition to C-mannosylation, TSR domains
usually display O-linked glycosylation of a Thr or Ser residue
that precedes the cysteine in loop A-B (35, 60, 61). This
glycosylation constitutes the attachment of a β-glucose-1,3-
α-fucose glycan through a linkage between the C1 atom of
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FIGURE 6 | A shorter Trp-ladder allows structural flexibility of TSR4.
(A) Cartoon representation of TSR4 from PN1/456 (yellow), PN12/456 (red), and
PN1/456-CTC (green). Structures were superposed using the STB domain,
shown in purple, as reference. The TSR4 domain is bent at the position of
V266 (shown in sticks) resulting in distances of 18.6 Å, 20.2 Å, and 28.3 Å
between the Cα-atoms of the N-terminal residues (S255) in each of the three
models. The angle between the proximal (residues 256–266 and 279–303)
and distal (residues 267–278 and 304–312) parts of TSR4 are indicated.
(B) Trp-ladder residues in TSR4 from PN1/456 (yellow) and PN12/456 (red)
showing the distortion of the TSR domain at the position of the missing third
tryptophan, which is replaced by Val266. (C) Trp-ladder residues in TSR5
(green) shown as representative for a prototypical TSR Trp-ladder, The
TSR-fold is stabilized by mannosyl-Trp/Arg H-bonds. Trp-ladder residues are
shown in sticks and electron density is shown at 1-rmsd contour level.
H-bonds are indicated as dashed lines.
the fucose and the Thr or Ser side chain oxygen (61). In
PN12/456, we observe O-fucosylation of TSR1 (Thr92), TSR2
(Thr151), and TSR4 (Thr272) (Figure 4B), although the TSR2
glycan is poorly defined. In all structures, the O-fucosylation
FIGURE 7 | Interactions between TSR5 and TSR6 stabilize the TSR6
β-hairpin. Cartoon representation of the TSR5/TSR6 (green/red) interface with
residues that form the hydrophobic core that stabilizes the TSR6 β-hairpin
shown in sticks.
of TSR4 is especially well-defined and is involved in properdin
oligomerization, as described below. Finally, we observe N-
glycosylation of Asn428, which is located in the B-C loop
insertion in TSR6 and has been shown not to be important in
properdin function (29).
Properdin Oligomerization
A previously reported model for properdin oligomerization
described the properdin vertex as a ring formed by four TSR
domains each comprising a quarter of the ring (13) and formed
by two inter protomer contacts (13, 27). The structures of PN1/456
and PN12/456 showed that the properdin vertex consists of the
STB domain, TSR1, part of TSR4, TSR5, and TSR6 domains.
These domains form a ring-like structure through interfaces
formed by the STB and TSR1 domains with TSR4 and TSR6,
respectively. TSR2 and ∼66% of TSR4 are protruding from the
vertex and form the properdin edges along with TSR3, which
is absent in PN1/456 and PN12/456. The boomerang-shaped TSR6
forms approximately half of the ring, with an extensive interface
between the distal end of TSR6 and TSR1, and the long insertion
in the B-C loop of TSR6 locked firmly in place by interactions
with TSR5 (Figure 7).
The interface between TSR6 and TSR1 is formed by the distal
end of TSR6, which includes the A-B loop and the C-terminal
region of strand C, and the β-sheet of TSR1 (Figures 8A,B).
This interface is predominantly mediated by hydrophobic
interactions, involving residues Leu99, Tyr101, Trp122, and
Leu124 from TSR1 and Pro399, Pro459, Pro464, Cys391-Cys455,
and Cys395-Cys461 from TSR6. In addition, hydrogen bonds are
formed between the backbone atoms of Leu124 from TSR1 and
Cys391 in TSR6, respectively, and between sidechains of Ser90
and Ser97 and the backbone carbonyl of His457 and Leu456,
respectively. Additionally, salt bridges are formed between Glu95
and Arg103 in TSR1 and Arg401 and Asp463 in TSR6. The
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FIGURE 8 | Properdin inter-protomer interfaces. (A) (top) Surface representation of PN12/456 colored by individual domains: STB (purple), TSR1 (blue), TSR2 (coral),
TSR4 (yellow), TSR5 (green), and TSR6 (red). (bottom) Individual TSR domains with atoms colored by interaction with the opposing protomer (contacts defined as
atoms within 5 Å). (B) Interactions between TSR1 and TSR6 with key residues involved in the interaction shown in stick representations. (C) As panel (B) for
interactions between STB and TSR4/5. For clarity disulphides are colored orange.
interaction between Glu95 and Arg401 is not visible in PN1/456-
CTC since the region containing Glu95 is not well-defined in
this structure.
The second interface between properdin protomers is formed
by the STB domain and TSR4 (Figures 8A,B). This interface
is characterized by a hydrophobic core involving Leu47, Val51,
Leu58, Phe62 from the STB domain and Leu275, Ile305, and
Pro311 in TSR4. In addition, there are hydrophilic interactions
between Asp55 and the backbone carbonyl moiety of Leu58
from the STB domain and Asn307 and the backbone nitrogen
of Cys312 of TSR4, respectively. The O-linked glycan on Thr272
from TSR4 contributes directly to the interaction via a hydrogen
bond with Asn59 on the STB domain as well as multiple water-
mediated interactions.
Interaction of Properdin With C3b
In PN1/456-CTC, properdin-TSR5 sits on top of the C3/C3b-
CTC domain with an ∼angle of 20◦ between the main body
of TSR5 and the C3/C3b-CTC C-terminal α-helix (Figure 9A).
This interface is characterized bymainly hydrophilic interactions,
involving TSR5 residues Gln343, Gln363, Gln364, His369, and
C3/C3b-CTC residues Gln1638, Gln1643, and Glu1654, and a
salt bridge between TSR5 Arg359 and C3/C3b-CTC Asp1639
(Figure 9B). The C-terminal end of the C3/C3b-CTC α-helix
is embraced by two loops, which resemble stirrups, formed by
the insertions in the core structure of properdin TSR5 and
TSR6, respectively (TSR5 res. 328–333 and TSR 6 res. 419–
426) (Figure 9C). The TSR6 stirrup is partially disordered in
the absence of C3/C3b-CTC, but well-defined in the PN1/456-
CTC complex. The two “stirrups” provide additional properdin-
C3b interactions; the TSR5 stirrup interacts with C3/C3b-CTC
through cation-pi stacking of Arg329 with C3/C3b Phe1659
and a hydrogen bond between Arg330 and the main-chain
oxygen of C3/C3b Gly1660. In the TSR6 stirrup, Lys427 forms
a salt bridge with C3/C3b Glu1654. This interaction is further
stabilized by hydrogen bonds between the TSR6 Glu422 side
chain with backbone atoms from Ser1571 and Thr1568 from
the C3/C3b-CTC domain and backbone mediated interactions
between Val421 and Glu422 from the TSR6 stirrup with C3/C3b
Val1657 and Val1658, respectively (Figure 9C).
To gain insights into the properdin interactions with the
C3bBb complex, we modeled and refined the structure of the
proteolytic fragment Pc in complex with the SCIN-stabilized
C3bBb convertase (PDB ID: 5M6W) (32). Modeling properdin
in the density of 5M6W (see section Materials and Methods)
resulted in a significant improvement of the refinement statistics
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FIGURE 9 | Properdin-convertase interactions. (A) Surface representation of PN1/456-CTC. Domains colored as follows: STB (purple), TSR1 (blue), TSR4 (yellow),
TSR5 (green), TSR6 (red) from properdin, the C3/C3b CTC domain (gray), and Bb (brown). (B) Detailed view of the interaction between TSR5 and the C3/C3b CTC
C-terminal α-helix. (C) Side view of PN1/456-CTC, 90◦ rotated compared to (B) showing details of the interaction between the TSR5 and TSR6 stirrup loops and
C3/C3b-CTC. In (B,C) proteins are shown in cartoon representation with side chains of key residues that are involved in the interaction shown in sticks. H-bonds are
indicated as dashed lines. (D) Detail of the properdin-C3bBb-SCIN complex showing electron density at 1-rmsd contour level. (E) Close-up of the properdin-C3b-Bb
interface showing the two properdin stirrup-loops that are sandwiched between C3b and Bb. Putative interaction in the properdin-C3bBb interface are shown as
sticks. (F) TSR4 from all five properdin structures that are described in this paper: PN1/456 (yellow), PN12/456 (red), PN1/456-CTC (green), and two copies of properdin
in the properdin-C3bBb-SCIN complex (purple and pink) with models superposed using the distal part of TSR4 (residues 267–278 and 304–312).
(Rfree/Rwork = 0.264/0.219, compared to Rfree/Rwork =
0.315/0.262, when not including properdin). The structure
comprises two copies of the SCIN stabilized C3bBbPc complex
with density for TSR3 only detectable in one copy (Figure 9D).
In both copies of the C3bBb-SCIN-Pc complex, the ring-like
structure of properdin and the interface with C3b are similar
Frontiers in Immunology | www.frontiersin.org 13 September 2019 | Volume 10 | Article 2097
van den Bos et al. Structures of Properdin and Properdin/C3b-CTC
as observed for PN1/456 in complex with C3/C3b CTC domain.
Although the stirrup loops of TSR5 and TSR6 are in the vicinity
of the VWA domain of Bb, we observe only two contacts between
properdin and Bb within 3.2 Å in the model. The side chains
of Lys350 (325 in 5M6W) of Bb and Val421 of properdin are
within 2.8 Å and the side chains Met394 (369 in 5M6W) of
Bb and Glu422 of properdin are within 3.1 Å distance, thus no
direct interactions are apparent between properdin and Bb in the
structural model (Figure 9E).
The two C3bBbPc complexes in the asymmetric unit show
variation in both TSR4 and TSR2-TSR3; In one of the complexes
the conformation of TSR4 is similar to that of TSR4 from PN1/456,
in the second C3bBbPc complex TSR4 is once again bent at the
position of V266, but at an angle that does not correspond to
TSR4 in PN1/456, PN112/456, or PN1/456-CTC, showing that TSR4
has an even greater range of motion. This structural variability of
the TSR4 conformation results in a∼60◦ that is covered by TSR4
in all properdin models (Figure 9F). Similarly, TSR2 also shows
structural flexibility; the orientation of TSR2 in one C3bBbPc
complex matches the orientation observed in PN12/456, whereas
in the other copy TSR2 is at a 58◦ angle compared to TSR2
from PN12/456 (Figure 10A). Using the different conformations
observed for TSR2 and TSR4 we were able to build models
for properdin dimers, trimers and tetramers bound to a C3bBb
coated surface (Figure 10B). In these models, the properdin ring-
like vertices (comprising STB, TSR1 and (the distal end of)
TSR4′, TSR5′, and TSR6′ (with domains from a second protomer
indicated by an apostrophe), are orientated perpendicular to the
plane of the surface, with the edges comprising TSR2, TSR3 and
the proximal part of TSR4 roughly parallel to the surface.
DISCUSSION
Previous biochemical data (11, 12, 21) has indicated that
properdin enhances complement activity by binding and
stabilizing surface-bound C3 pro-convertases (C3bB) and
convertases (C3bBb) of the alternative-pathway. Low-resolution
structural data suggested that properdin binds C3 convertases
at the α′-chain of C3b (13, 32), consistent with stabilization
through putative bridging interactions between C3b and FB or
fragment Bb of the pro-convertase and convertase, respectively.
The crystallographic data presented here has provided atomic
models of the ring-shaped structures previously observed in
low-resolution EM images of full-length oligomeric properdin
(13, 27) and in a crystal of C3bBb-SCIN in complex with
the proteolytic Pc fragment at 6-Å resolution (32). Our high-
resolution data reveals the STB-domain fold adopted by the N-
terminal domain, the structural variations and post-translational
modifications present in the TSR domains and the non-covalent
binding interfaces between N-terminal domains STB and TSR1
and C-terminal domains TSR4 and TSR6, respectively, of two
different protomers needed to form the ring-shaped structures
of properdin. Next, our data of properdin in complex with the
CTC domain of C3b shows the interaction details that position
properdin on top of a C3b molecule, when C3b is covalently
bound to a target surface, and identified two “stirrup-like”
loops, formed by inserts into TSR-folds of TSR5 and TSR6, as
interaction sites for binding the VWA domain of FB and Bb for
stabilizing the C3 pro-convertase and convertase, respectively.
Mass spectrometry of plasma-derived full-length properdin
indicated complete C-mannosylation of 14 out of the 17
tryptophans present in the WRWRWR motifs and no or partial
C-mannosylation of the remaining three (Trp80, 202, and 318),
in addition to three fully (Thr151, Ser208, and Thr272) and
one partially occupied (Thr92) O-fucosylation sites and a single
N-linked glycosylation site (Asn428) (34, 35) (Figure 4B). We
observed that the C-mannosyl moieties on tryptophan are part
of common H-bonding networks that also include the backbone
nitrogen of the mannosylated Trp (positioned on strand A),
the guanidium head group of the arginine distal to the Trp
(in strand B) and a polar or negatively charged side chain of
the residue opposing the Arg (in strand C), thus bridging all
three strands providing stabilization to the TSR fold (Figure 6C).
Similar arrangements are found in the structure of TSR domains
of C8 (PDB ID: 3OJY), C9 (PDB ID 6CXO), ADAMTS13 (PDB
ID:3VN4), and Unc5a (PDBID: 4V2A). In the case of Unc5a
(determined at 2.4-Å resolution), the two mannosyl moieties
have not been included in the model, but are clearly visible in the
density in a conformation similar to that observed in properdin.
In C6 structures (3T5O, 4E0S, 4A5W), the mannoses in TSR1
and TSR3 domains are absent or modeled in various alternative
conformations, possibly due to the relatively low resolution of
these structures, ranging from 2.9 to 4.2 Å. In our structures,
we observed clear density for all mannosyl moieties, except
two (Trp86 and Trp145), of the reported fully C-mannosylated
tryptophans (35). Trp145 is located on TSR2, which exhibits
overall poor density in the crystal structure of PN12/456. Very
weak densities for a mannosyl moiety at Trp86 of TSR1 were
observed in all three structures. The WRWRWR motif in TSR1
lacks the final arginine residue, instead a glutamine residue is
observed at this position. Most likely, the absence of H-bonding
potential with a guanidinium moiety at the final position causes
local flexibility, explaining the weak density observed for the
mannosyl on Trp86. Properdin is N-glycosylated at Asn428 of
TSR6, which is located at the base of the β-hairpin insertion.
In our structures this glycan is only partially present, however,
there is clear density for this glycan in 5M6W. This glycan would
not interact with C3bBb upon binding, which is in agreement
with previous findings that removal of N-linked glycans had no
effect on properdin activity in a hemolytic assay (29). Properdin
O-fucosylation is observed in the density at Thr92, Thr151,
and Thr272, which are positioned at structural homologous
positions in the A-B-loop of TSR1, TSR2, and TSR4. The A-
B loop in 63 out of 88 TSR sequences contains the sequence
C-X-X-S/T-C, where the serine or threonine is O-fucosylated
(60). Similar to TSR1 from C6 and the TSR domain from
ADAMTS13, the O-glucosyl-β1,3-fucose is packed against the
disulphide bridge that connects loop A-B to the terminal residue
of the TSR domain.
Oligomeric full-length properdin consists of ring-shaped
vertices, formed by N- and C-terminal domains of separate
protomers (13, 27). The crystal structures of PN1/456 and PN12/456,
obtained by co-expression of N- and C-terminal parts, clearly
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FIGURE 10 | Models of properdin oligomers binding to surface bound C3 convertases. (A) Structures of PN1/456 (red), PN12/456 (yellow), PN1/456-CTC (green), and
the copy from Pc-C3bBb-SCIN lacking density for TSR3 (pink) superimposed on TSR5 of the other copy of Pc-C3bBb-SCIN (purple). (B) Ribbon representation of
properdin oligomers binding to C3 convertases viewed from the front (left) and top (right). C3b and Bb are colored gray and wheat, respectively, Gln1013 from the C3b
thioester is shown as red spheres. Each protomer in a properdin oligomers is colored differently. Top: Properdin dimer binding to two C3 convertases (for this model
we used PN12/456 with TSR3 positioned relative to TSR2 as it is in the copy of Pc-C3bBb-SCIN that contains TSR3) Middle: Properdin trimer binding to 3 C3
convertases (for this model the properdin copy from Pc-C3bBb-SCIN that contains TSR3 was used). Bottom: Properdin tetramer binding to four C3 convertases (this
model was generated with TSR2 as in the middle panel but using TSR4 from PN1/456).
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revealed that the ring-shaped vertices are formed by two contact
interfaces between N-terminal domains of one protomer and
the C-terminal domains of another protomer (Figure 4A). The
N-terminal domain adopts a STB fold and binds the TSR4′
domain of another protomer. This interface, which is dominated
by hydrophobic interactions, is further stabilized by additional
H-bonds between STB Asn59 and the O-glucosyl-β1,3-fucose
on Thr272 of TSR4′. A second protomer-protomer interface is
observed between TSR1 and TSR6′. This interface is formed
between the distal end of TSR6′ and the β-sheet at the core of
TSR1 and involves hydrophobic interactions as well as several
H-bonds and two salt bridges. Overall, the ring-shaped vertex
of properdin is formed by STB-TSR1 of one protomer and
(approximately ∼1/3 of) TSR4′, TSR5′ and, an extended and
curved, TSR6′ of a second protomer (Figure 8). TSR2, TSR3,
and the remaining part of TSR4 consequently form the edges in
properdin oligomers.
Consistent with low-resolution EM and X-ray data (13, 32),
we have shown that the TSR5 domain of properdin provides
the main interaction interface with C3b by binding along the
length of the C-terminal α-helix of the C3b α′-chain (Figure 9A).
Protonation of properdin His369, at this main interface, would
yield formation of a salt-bridge with C3b Glu1654 (Figure 9C),
explaining increased binding of properdin to C3b at low pH
(32, 62). Comparison with other structures of C3b (37) indicates
that binding of properdin to the CTC domain does not require
nor likely induces large conformational changes in C3b. We
identified two “stirrup”-like loops, residues 328–336 of TSR5
and 419–426 of TSR6, which embrace the end of the C-
terminal α-helix of CTC (Figure 9C). Cleavage of properdin
in the TSR5-stirrup loop (between res. 333–334) leads to loss
of C3b binding (and, hence, loss of convertase stabilization)
(29), which indicates the importance of an intact TSR5 stirrup
in C3b binding. The only known properdin type III (loss-of-
function) mutation, Y414D (63), is located at the base of the
TSR6 β-hairpin that constitutes the TSR6 stirrup. Tyr414 is part
of a hydrophobic core between TSR5 and TSR6 (Figure 7) and
Y414D likely disturbs this hydrophobic core and destabilizes
the TSR6 stirrup and hence affects C3b binding or convertase
stabilization (63).
Monomerized properdin binds the C3 convertase (C3bBb)
and pro-convertase (C3bB) strongly, and C3b weakly (KD′s
of 34 nM, 98 nM, and 6.8µM, respectively, in agreement with
previous data (12, 32); Figures 2, 3). Superposition of PN1/456-
CTC onto C3bB and C3bBD (PDB ID: 2XWJ and 2XWB) (39)
suggests that the two stirrups are ideally positioned to bridge
interactions between C3b and the VWA domain of FB and Bb.
The TSR5 stirrup is in close proximity to the N-terminal region
of CCP1 in the Ba region of FB, with only one potential H-
bond between properdin Asn331 and FB Ser78. The proximity
of properdin to FB-CCP1 explains the cross-links observed
between Ba and properdin by Farries et al. (64). Re-analysis
of C3bBb-SCIN with Pc (at 6-Å resolution) is consistent with
the interactions that we observed at high resolution between
PN1/456 and an isolated C3/C3b-CTC domain (Figures 9D,E).
The low-resolution data of Pc-C3bBb-SCIN suggests small
rearrangements in the TSR6 stirrup loop. Nevertheless, the
expected additional interactions between Bb and properdin
are not observed in Pc-C3bBb-SCIN. Potentially, the inhibitor
SCIN enforces a C3bBb conformation that is not compatible
with stabilization by properdin (32). Therefore, the interaction
details between properdin and FB and Bb that explain higher
binding affinities for the pro-convertase and convertase remain
unfortunately unresolved.
FIGURE 11 | Properdin binding to C3b is incompatible with FI binding. Superposition of PN1/456-CTC and C3b-FH-FI (PDB ID: 5O32). Models were superposed on
the C3b-CTC domains (rmsd 0.7 Å). Left: overview of the structures with FH (Pink), FI (light blue), and properdin (multicolored model, with TSR5 in green and TSR6 in
red) in ribbon presentation with semi-transparent molecular surface and C3b (gray) shown in ribbon. Right: close up showing FI occupies the same space as the
properdin TSR6 (red) stirrup loop.
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Besides promoting the formation of, and stabilizing the
alternative-pathway C3 convertase, properdin is also known
to inhibit FI activity (12, 13, 65); based on kinetic data,
this is likely due to competition for the same binding
site on C3b (12). Superposition of PN1/456-CTC with C3b
in complex with FH and FI (66) (PDB ID: 5O32) shows
that, in a putative properdin-C3b-FH-FI complex, TSR6
of properdin severely clashes with the FI membrane-attack
complex domain in FI (Figure 11). Therefore, the structural
data supports competitive binding of properdin and FI for
the same binding site. No overlaps are observed between
properdin and regulators FH, DAF and MCP, when superposing
PN1/456-CTC with other C3b-regulator complexes (37). Thus,
reduced decay-acceleration activity of FH and DAF (32) is
most likely due to the increased stability of C3bBb upon
properdin binding.
Native properdin occurs predominantly as a mixture of
dimers, trimers and tetramers (8), observed as flexible lines,
triangles and quadrilaterals in negative-stain EM (13, 27).
The oligomers bind with high avidity (with an apparent KD
of 22 nM) to surface-bound C3b compared to monomerized
properdin binding a single C3b (KD of 6.8µM). Consistently,
properdin tetramers are more active than trimers, which are
more active than dimers (8, 9). In the structures presented
here, overlaid in Figure 10A, we observed structural variability
predominantly in TSR2 and TSR4. These variations occur
mostly in the plane of the membrane of a properdin oligomer
bound to an opsonized surface, which allowed us to create
composite models representing symmetric properdin dimers,
trimers and tetramers binding to surface-bound C3b, C3bB,
or C3bBb in a straightforward manner (Figure 10B). The
ability of properdin to form flexible oligomers is crucial
to enhance complement activation only on surfaces by
binding deposited C3b molecules with high avidity, while
promoting convertase formation (11) and stabilizing formed
convertases by binding C3bB and C3bBb complexes with high
affinity (12, 32). Local production of properdin by immune
cells would result in further enhancement near affected
sites (23, 25, 26).
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